Literature DB >> 34421146

Struggling to find Effective Pharmacologic Options for Akathisia? B-CALM!

Srinagesh Mannekote Thippaiah1, Rachel E Fargason1, Badari Birur1.   

Abstract

Akathisia is a movement disorder affecting the trunk and limbs, characterized by subjective and objective restlessness. Key signs include continual, repetitive rocking, leg shuffling, and fidgeting. Antipsychotic-induced akathisia is optimally managed by reducing the medication dose or switching to a second generation antipsychotic that is less prone to inducing akathisia. However, since medication changes are often not feasible, we review the available classes of rescue agents for akathisia symptoms. The fitting acronym, "B-CALM", which stands for Beta-blockers, Clonazepam, Anticholinergics, cLonidine and Mirtazapine, will assist prescribers in facile recall of evidence-based treatment options for akathisia. Pharmacological agents such as mianserin, trazodone, Vit B6, amantadine, gabapentin, and pregabalin have also been examined as treatment options for antipsychotic-induced akathisia. Although initial exploratory reports on these agents have been promising, the current evidence is insufficient. Akathisia has a good prognosis when managed early in the course of treatment. A variety of safe rescue agents are available for the management of this condition, however, current evidence best supports the use of propranolol and mirtazapine.
Copyright © 1964–2021 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  akathisia; beta-blockers; medication side-effects; mirtazapine; motor restlessness; pharmacological options

Mesh:

Substances:

Year:  2021        PMID: 34421146      PMCID: PMC8374932     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  9 in total

1.  A rating scale for drug-induced akathisia.

Authors:  T R Barnes
Journal:  Br J Psychiatry       Date:  1989-05       Impact factor: 9.319

2.  Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

Authors:  R Davis; M I Wilde
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 3.  The clinical challenges of akathisia.

Authors:  James B Lohr; Carolyn A Eidt; Areej Abdulrazzaq Alfaraj; Mounir A Soliman
Journal:  CNS Spectr       Date:  2015-12       Impact factor: 3.790

Review 4.  Iloperidone, asenapine and lurasidone: a primer on their current status.

Authors:  Frank I Tarazi; Stephen M Stahl
Journal:  Expert Opin Pharmacother       Date:  2012-07-31       Impact factor: 3.889

5.  Clonidine in neuroleptic-induced akathisia.

Authors:  L A Adler; B Angrist; E Peselow; J Reitano; J Rotrosen
Journal:  Am J Psychiatry       Date:  1987-02       Impact factor: 18.112

6.  Use of clonidine in treating neuroleptic-induced akathisia.

Authors:  G S Zubenko; B M Cohen; J F Lipinski; J M Jonas
Journal:  Psychiatry Res       Date:  1984-11       Impact factor: 3.222

7.  The Assessment and Treatment of Antipsychotic-Induced Akathisia.

Authors:  Tamara Pringsheim; David Gardner; Donald Addington; Davide Martino; Francesca Morgante; Lucia Ricciardi; Norman Poole; Gary Remington; Mark Edwards; Alan Carson; Thomas R E Barnes
Journal:  Can J Psychiatry       Date:  2018-04-23       Impact factor: 4.356

Review 8.  Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy.

Authors:  Fernanda S Tonin; Astrid Wiens; Fernando Fernandez-Llimos; Roberto Pontarolo
Journal:  Core Evid       Date:  2016-12-14

Review 9.  Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.

Authors:  Haitham Salem; Caesa Nagpal; Teresa Pigott; Antonio Lucio Teixeira
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  9 in total
  1 in total

Review 1.  Antiseizure Drugs and Movement Disorders.

Authors:  Michel Sáenz-Farret; Marina A J Tijssen; Dawn Eliashiv; Robert S Fisher; Kapil Sethi; Alfonso Fasano
Journal:  CNS Drugs       Date:  2022-07-21       Impact factor: 6.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.